Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which ...

The U.S. FDA posted notice of six class I device recalls between June 3 and June 5, 2025, four of which are for corrections.

The EMA’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending European orphan drug designation for Hemispherian AS’s GLIX-1 for the treatment of glioma.

Seyltx Inc. has entered into an option agreement with Neurop Inc. for a portfolio of novel GluN2B antagonists. The compounds include NP-10679, which has completed phase I, and seven preclinical ...

Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors reported to be useful for the treatment of ...

Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic ...

Aqilion AB has released promising results from new studies with molecules from the company’s lead series within the TAK1 program, demonstrating a strong disease-modifying effect in a well-established ...

Immunoprecise Antibodies Ltd. has discovered a highly conserved epitope across all four dengue virus serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) using its proprietary Lensai platform powered by its ...